JP6929951B2 - 抗ｌａｇ−３抗体およびその使用 - Google Patents

抗ｌａｇ−３抗体およびその使用 Download PDF

Info

Publication number
JP6929951B2
JP6929951B2 JP2019544658A JP2019544658A JP6929951B2 JP 6929951 B2 JP6929951 B2 JP 6929951B2 JP 2019544658 A JP2019544658 A JP 2019544658A JP 2019544658 A JP2019544658 A JP 2019544658A JP 6929951 B2 JP6929951 B2 JP 6929951B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
lag
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019544658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508303A5 (enExample
JP2020508303A (ja
Inventor
ファン、レイ
ワン、ゼンイ
グオ、ビンシ
ザン、ジンウ
ジアン、ウェンキン
ワン、ヨンチアン
Original Assignee
アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド
アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/074365 external-priority patent/WO2018152687A1/en
Application filed by アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド, アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド filed Critical アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド
Publication of JP2020508303A publication Critical patent/JP2020508303A/ja
Publication of JP2020508303A5 publication Critical patent/JP2020508303A5/ja
Application granted granted Critical
Publication of JP6929951B2 publication Critical patent/JP6929951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2019544658A 2017-02-22 2018-02-22 抗ｌａｇ−３抗体およびその使用 Active JP6929951B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2017/074365 WO2018152687A1 (en) 2017-02-22 2017-02-22 Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CNPCT/CN2017/074365 2017-02-22
CN2017088570 2017-06-16
CNPCT/CN2017/088570 2017-06-16
PCT/CN2018/076940 WO2018153340A1 (en) 2017-02-22 2018-02-22 Anti-lag-3 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2020508303A JP2020508303A (ja) 2020-03-19
JP2020508303A5 JP2020508303A5 (enExample) 2020-06-25
JP6929951B2 true JP6929951B2 (ja) 2021-09-01

Family

ID=63253327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019544658A Active JP6929951B2 (ja) 2017-02-22 2018-02-22 抗ｌａｇ−３抗体およびその使用

Country Status (12)

Country Link
US (2) US10577421B2 (enExample)
EP (1) EP3389702A4 (enExample)
JP (1) JP6929951B2 (enExample)
KR (2) KR102144317B1 (enExample)
CN (1) CN109475617B (enExample)
AU (1) AU2018226298B2 (enExample)
CA (1) CA3053989C (enExample)
IL (1) IL268734A (enExample)
NZ (1) NZ756678A (enExample)
SG (1) SG11201907561PA (enExample)
WO (1) WO2018153340A1 (enExample)
ZA (1) ZA201905790B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI875679B (zh) 2017-07-06 2025-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN110678484B (zh) * 2018-08-21 2022-12-27 天境生物科技(杭州)有限公司 抗pd-l1/抗lag3双特异性抗体及其用途
EP3833693A4 (en) * 2018-08-21 2023-06-07 ABL Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CN110066334B (zh) * 2019-03-22 2020-03-10 南京医科大学 抗Galectin-3的全人源化单域抗体及应用
CN112010976B (zh) * 2019-05-29 2022-07-01 山东博安生物技术股份有限公司 抗lag3抗体及其用途
CN110320367A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
KR102444797B1 (ko) * 2019-06-14 2022-09-20 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CN112513097B (zh) * 2019-07-11 2021-10-29 武汉友芝友生物制药有限公司 四价对称双特异性抗体
EP4039711A4 (en) * 2019-07-23 2023-11-15 Nanjing GenScript Biotech Co., Ltd. BISPECIFIC ANTI-CD47/ANTI-LAG-3 ANTIBODY, PREPARATION METHOD AND USE THEREOF
CN113004407B (zh) * 2019-12-20 2022-11-11 广东菲鹏制药股份有限公司 Lag3抗体及其应用
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN116023484A (zh) * 2020-05-19 2023-04-28 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN115490764B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Lgals3的表位肽及所述表位肽与热休克蛋白的复合物
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250198990A1 (en) * 2022-03-15 2025-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods of Identifying Anti-LAG-3 Agents
CN115819595B (zh) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 一种抗lag3纳米抗体及其制备方法与应用
WO2024189628A1 (en) * 2023-03-16 2024-09-19 Technion Research And Development Foundation Limited Lag-3 inhibition for enhanced antiviral immune response
WO2024196072A1 (ko) * 2023-03-20 2024-09-26 경북대학교 산학협력단 Lag-3에 결합하는 펩타이드 및 이의 용도
WO2025040080A1 (en) * 2023-08-21 2025-02-27 Beigene Switzerland Gmbh Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
US20250197493A1 (en) * 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
MY210104A (en) * 2013-03-15 2025-08-27 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
CN106029694A (zh) * 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
EP3660050A1 (en) * 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI733687B (zh) * 2015-07-22 2021-07-21 美商索倫多醫療公司 結合ｌａｇ３之抗體治療劑
SG10202010506TA (en) * 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof

Also Published As

Publication number Publication date
US20200071403A1 (en) 2020-03-05
AU2018226298A1 (en) 2019-09-19
CA3053989C (en) 2024-10-29
CN109475617A (zh) 2019-03-15
NZ756678A (en) 2023-02-24
US20190225687A1 (en) 2019-07-25
WO2018153340A1 (en) 2018-08-30
US11414485B2 (en) 2022-08-16
AU2018226298B2 (en) 2022-02-17
IL268734A (en) 2019-10-31
CN109475617B (zh) 2022-05-17
EP3389702A4 (en) 2019-08-14
ZA201905790B (en) 2025-03-26
EP3389702A1 (en) 2018-10-24
KR102144317B1 (ko) 2020-08-18
US10577421B2 (en) 2020-03-03
KR20180113195A (ko) 2018-10-15
KR102236259B1 (ko) 2021-04-06
KR20190111894A (ko) 2019-10-02
SG11201907561PA (en) 2019-09-27
JP2020508303A (ja) 2020-03-19
CA3053989A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP6929951B2 (ja) 抗ｌａｇ−３抗体およびその使用
JP7320555B2 (ja) グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
JP6896989B2 (ja) 抗体結合ｌａｇ−３及びその使用
JP6797137B2 (ja) Ｏｘ４０に対する抗体およびその使用
JP7038064B2 (ja) ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
CN111886256B (zh) 抗mica和/或micb抗体及其用途
TWI780057B (zh) 針對tim3之抗體及其用途
JP6983776B2 (ja) グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
JP6873992B2 (ja) プログラム死リガンド（ｐｄｌ１）に対する単一ドメイン抗体およびその誘導体タンパク質
CN109641037B (zh) 抗psma抗体及其用途
JP2020515239A (ja) 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
AU2018336520B2 (en) Novel anti-CD19 antibodies
WO2018152687A1 (en) Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
JP2021511026A (ja) Ｔｉｍ３に対する抗体およびその使用
JP2021520850A (ja) Ｐｄ−１結合抗体及びその使用
JP2021509275A (ja) 抗ｃｄ４０抗体およびその使用
HK1262681A1 (en) Anti-lag-3 antibodies and uses thereof
HK1262681B (en) Anti-lag-3 antibodies and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200511

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210811

R150 Certificate of patent or registration of utility model

Ref document number: 6929951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250